- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
More ▼
Key statistics
On Friday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 16.18, 111.78% above the 52 week low of 7.64 set on Dec 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.77 |
---|---|
High | 16.97 |
Low | 15.94 |
Bid | -- |
Offer | -- |
Previous close | 16.78 |
Average volume | 1.06m |
---|---|
Shares outstanding | 57.63m |
Free float | 55.02m |
P/E (TTM) | -- |
Market cap | 932.52m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼